All Stories

  1. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743

    Article • Journal of Clinical Oncology, July 2026, American Society of Clinical Oncology (ASCO)

    Prof Luciano Mutti

  2. Dental Pulp Stem Cell-Derived Organoids: Advancing the Development of 3D Structures

    Article • Cells, October 2025, MDPI AG

    Prof Luciano Mutti

  3. “WEE”ding Out Resistance to Osimertinib in the “ARID”1A-Mutated Badlands

    Article • Journal of Thoracic Oncology, October 2025, Elsevier

    Prof Luciano Mutti

  4. Reducing clinical target volume margins for multifocal glioblastoma: a multi-institutional analysis of patterns of recurrence and treatment response

    Article • Radiation Oncology Journal, March 2025, Korean Society for Therapeutic Radiology and Oncology (KAMJE)

    Prof Luciano Mutti

  5. Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer

    Article • Journal of Thoracic Oncology, August 2024, Elsevier

    Prof Luciano Mutti

  6. Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma

    Article • Journal of Thoracic Oncology, April 2024, Elsevier

    Prof Luciano Mutti

  7. Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis

    Article • Cancers, March 2024, MDPI AG

    Prof Luciano Mutti

  8. The Impact of 3D Nichoids and Matrix Stiffness on Primary Malignant Mesothelioma Cells

    Article • Genes, February 2024, MDPI AG

    Prof Luciano Mutti

  9. Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies?

    Article • Frontiers in Oncology, September 2023, Frontiers

    Prof Luciano Mutti

  10. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo

    Article • Biology Direct, April 2023, Springer Science + Business Media

    Prof Luciano Mutti

  11. Editorial: Prognostic factors in non-small cell lung cancer

    Article • Frontiers in Oncology, March 2023, Frontiers

    Prof Luciano Mutti

  12. Intratumor microbiota as a novel potential prognostic indicator in mesothelioma

    Article • Frontiers in Immunology, March 2023, Frontiers

    Prof Luciano Mutti

  13. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review

    Article • La radiologia medica, February 2023, Springer Science + Business Media

    Prof Luciano Mutti

  14. The function and clinical implication of YTHDF1 in the human system development and cancer

    Article • Biomarker Research, January 2023, Springer Science + Business Media

    Prof Luciano Mutti

  15. Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology

    Article • Journal of Translational Medicine, December 2022, Springer Science + Business Media

    Prof Luciano Mutti

  16. European Respiratory Society guideline on various aspects of quality in lung cancer care

    Article • European Respiratory Journal, November 2022, European Respiratory Society (ERS)

    David Baldwin, Prof Luciano Mutti

  17. Neuro–Immune Interactions in Severe COVID-19 Infection

    Article • Pathogens, October 2022, MDPI AG

    Prof Luciano Mutti

  18. The function and clinical implication of circular RNAs in lung cancer

    Article • Frontiers in Oncology, October 2022, Frontiers

    Prof Luciano Mutti

  19. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

    Article • Frontiers in Oncology, September 2022, Frontiers

    Prof Luciano Mutti

  20. Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD

    Article • Frontiers in Oncology, July 2022, Frontiers

    Prof Luciano Mutti

  21. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations

    Article • Journal of Thoracic Oncology, July 2022, Elsevier

    Prof Luciano Mutti

  22. Abemaciclib for malignant pleural mesothelioma

    Article • The Lancet Oncology, June 2022, Elsevier

    Prof Luciano Mutti

  23. Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy

    Article • The Lancet Oncology, June 2022, Elsevier

    Prof Luciano Mutti

  24. A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma

    Article • Cancers, May 2022, MDPI AG

    Prof Luciano Mutti

  25. Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma

    Article • Frontiers in Oncology, May 2022, Frontiers

    Prof Luciano Mutti

  26. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma

    Article • JAMA Network Open, March 2022, American Medical Association (AMA)

    Prof Luciano Mutti

  27. Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?

    Article • Journal of Thoracic Oncology, February 2022, Elsevier

    Prof Luciano Mutti

  28. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?

    Article • The Lancet Oncology, January 2022, Elsevier

    Prof Luciano Mutti

  29. Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer

    Article • International Journal of Molecular Sciences, December 2021, MDPI AG

    Prof Luciano Mutti

  30. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis

    Article • Life, November 2021, MDPI AG

    Prof Luciano Mutti

  31. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy

    Article • International Journal of Molecular Sciences, August 2021, MDPI AG

    Prof Luciano Mutti

  32. Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study

    Article • Cancers, May 2021, MDPI AG

    Prof Luciano Mutti

  33. Identification of Overexpressed Genes in Malignant Pleural Mesothelioma

    Article • International Journal of Molecular Sciences, March 2021, MDPI AG

    Prof Luciano Mutti

  34. Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state

    Article • Oncology Reports, October 2020, Spandidos Publications

    Prof Luciano Mutti

  35. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis

    Article • Cells, August 2020, MDPI AG

    Prof Luciano Mutti

  36. HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy

    Article • International Journal of Molecular Sciences, July 2020, MDPI AG

    Prof Luciano Mutti

  37. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives

    Article • Translational Lung Cancer Research, February 2020, AME Publishing Company

    Prof Luciano Mutti

  38. Tumour Treating Fields for mesothelioma

    Article • The Lancet Oncology, January 2020, Elsevier

    Prof Luciano Mutti

  39. Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress

    Article • Frontiers in Oncology, September 2019, Frontiers

    Prof Luciano Mutti

  40. What can independent research for mesothelioma achieve to treat this orphan disease?

    Article • Expert Opinion on Investigational Drugs, July 2019, Taylor & Francis

    Prof Luciano Mutti

  41. The Biochemical Role of the Human NEIL1 and NEIL3 DNA Glycosylases on Model DNA Replication Forks

    Article • Genes, April 2019, MDPI AG

    Prof Luciano Mutti

  42. When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

    Article • Frontiers in Endocrinology, February 2019, Frontiers

    Prof Luciano Mutti

  43. BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment

    Article • International Journal of Molecular Sciences, January 2019, MDPI AG

    Prof Luciano Mutti

  44. ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe

    Article • European Respiratory Journal, October 2018, European Respiratory Society (ERS)

    Prof Luciano Mutti, David Baldwin

  45. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification

    Article • Journal of Translational Medicine, October 2018, Springer Science + Business Media

    Prof Luciano Mutti

  46. Scientific Advances and New Frontiers in Mesothelioma Therapeutics

    Article • Journal of Thoracic Oncology, September 2018, Elsevier

    Prof Luciano Mutti

  47. A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma

    Article • Cancer Research, August 2018, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  48. Surgery for malignant pleural mesothelioma: an international guidelines review

    Article • Journal of Thoracic Disease, January 2018, AME Publishing Company

    Prof Luciano Mutti

  49. Insight into glucocorticoid receptor signalling through interactome model analysis

    Article • PLoS Computational Biology, November 2017, PLOS

    Prof Luciano Mutti

  50. Immunotherapy advances for mesothelioma treatment

    Article • Expert Review of Anticancer Therapy, July 2017, Taylor & Francis

    Prof Luciano Mutti

  51. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

    Article • Expert Opinion on Investigational Drugs, July 2017, Taylor & Francis

    Prof Luciano Mutti

  52. Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma

    Article • PLOS One, June 2017, PLOS

    Prof Luciano Mutti

  53. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism

    Article • Scientific Reports, June 2017, Springer Science + Business Media

    Prof Luciano Mutti

  54. Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia

    Article • PLOS One, June 2017, PLOS

    Prof Luciano Mutti

  55. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

    Article • Stem Cell Research & Therapy, May 2017, Springer Science + Business Media

    Prof Luciano Mutti, Professor Tullio Florio

  56. Current and prospective pharmacotherapies for the treatment of pleural mesothelioma

    Article • Expert Opinion on Orphan Drugs, May 2017, Taylor & Francis

    Prof Luciano Mutti

  57. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals

    Article • Occupational and Environmental Medicine, March 2017, BMJ

    Prof Luciano Mutti

  58. Anti-CTLA-4 therapy for malignant mesothelioma

    Article • Immunotherapy, March 2017, Future Medicine

    Prof Luciano Mutti

  59. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines

    Article • Genes & Cancer, February 2017, Impact Journals, LLC

    Prof Luciano Mutti

  60. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment

    Article • Genes & Cancer, January 2017, Impact Journals, LLC

    Prof Luciano Mutti

  61. New standard for assessing asbestos exposure and its consequences?

    Article • Occupational and Environmental Medicine, July 2016, BMJ

    Prof Luciano Mutti

  62. Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

    Article • Oncotarget, May 2016, Impact Journals, LLC

    Prof Luciano Mutti

  63. The role of microenvironment and immunity in drug response in leukemia

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, March 2016, Elsevier

    Prof Luciano Mutti

  64. Targeting hypoxic response for cancer therapy

    Article • Oncotarget, February 2016, Impact Journals, LLC

    Prof Luciano Mutti

  65. Tremelimumab for the treatment of malignant mesothelioma

    Article • Expert Opinion on Biological Therapy, December 2015, Informa Healthcare

    Prof Luciano Mutti

  66. Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Prof Luciano Mutti

  67. Expression status of candidate genes in mesothelioma tissues and cell lines

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, January 2015, Elsevier

    Prof Luciano Mutti, Prof Silvia Pellegrini

  68. A Common Polymorphism Within MSLN Affects miR-611 Binding Site and Soluble Mesothelin Levels in Healthy People

    Article • Journal of Thoracic Oncology, November 2014, Elsevier

    Prof Luciano Mutti

  69. “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

    Article • Medical Oncology, July 2014, Springer Science + Business Media

    Prof Luciano Mutti

  70. MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma

    Article • PLOS One, January 2014, PLOS

    Prof Luciano Mutti

  71. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, December 2013, Elsevier

    Prof Luciano Mutti

  72. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

    Article • The Lancet Oncology, October 2013, Elsevier

    Prof Luciano Mutti

  73. Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo

    Article • Oncogenesis, September 2013, Springer Science + Business Media

    Prof Luciano Mutti

  74. Therapies currently in Phase II trials for malignant pleural mesothelioma

    Article • Expert Opinion on Investigational Drugs, July 2013, Informa Healthcare

    Prof Luciano Mutti

  75. Preclinical Demonstration of Synergistic Active Nutrients/Drug (AND) Combination as a Potential Treatment for Malignant Pleural Mesothelioma

    Article • PLOS One, March 2013, PLOS

    Prof Luciano Mutti

  76. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

    Article • Journal of Cellular and Molecular Medicine, January 2013, Wiley

    Prof Luciano Mutti

  77. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma

    Article • European Journal of Cancer, November 2012, Elsevier

    Prof Luciano Mutti

  78. Epigallocatechin-3-gallate induces mesothelioma cell deathviaH2O2−dependent T-type Ca2+channel opening

    Article • Journal of Cellular and Molecular Medicine, October 2012, Wiley

    Prof Luciano Mutti

  79. Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma

    Article • PLOS One, May 2012, PLOS

    Prof Luciano Mutti

  80. Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma

    Article • Expert Opinion on Medical Diagnostics, April 2012, Informa Healthcare

    Prof Luciano Mutti

  81. Sustained Expression of Steroid Receptor Coactivator SRC-2/TIF-2 is Associated with Better Prognosis in Malignant Pleural Mesothelioma

    Article • Journal of Thoracic Oncology, January 2012, Elsevier

    Prof Luciano Mutti

  82. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications

    Article • Journal of Cellular Physiology, July 2011, Wiley

    Prof Luciano Mutti

  83. Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib

    Article • PLOS One, November 2010, PLOS

    Professor Paolo Pinton, Prof Luciano Mutti

  84. Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?

    Article • Current Medicinal Chemistry, September 2010, Bentham Science Publishers

    Prof Luciano Mutti

  85. Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma

    Article • The International Journal of Biological Markers, July 2010, SAGE Publications

    Prof Luciano Mutti

  86. Translational therapies for malignant pleural mesothelioma

    Article • Expert Review of Respiratory Medicine, April 2010, Taylor & Francis

    Prof Luciano Mutti

  87. Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation

    Article • Current Cancer Drug Targets, March 2010, Bentham Science Publishers

    Prof Luciano Mutti, Professor Tullio Florio

  88. MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications

    Article • American Journal of Respiratory Cell and Molecular Biology, March 2010, American Thoracic Society

    Prof Luciano Mutti

  89. In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells

    Article • BMC Cancer, February 2010, Springer Science + Business Media

    Prof Luciano Mutti

  90. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism

    Article • Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, December 2009, Elsevier

    Prof Luciano Mutti

  91. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

    Article • European Respiratory Journal, August 2009, European Respiratory Society (ERS)

    Prof Luciano Mutti

  92. Malignant pleural mesothelioma: current treatments and emerging drugs

    Article • Expert Opinion on Emerging Drugs, June 2009, Informa Healthcare

    Prof Luciano Mutti

  93. Estrogen Receptor-  Affects the Prognosis of Human Malignant Mesothelioma

    Article • Cancer Research, June 2009, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  94. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma

    Article • European Respiratory Journal, May 2009, European Respiratory Society (ERS)

    Prof Luciano Mutti

  95. In Arrayed Ranks: Array Technology in the Study of Mesothelioma

    Article • Journal of Thoracic Oncology, March 2009, Elsevier

    Prof Luciano Mutti

  96. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution

    Article • Journal of Infection, January 2009, Elsevier

    Prof Luciano Mutti

  97. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

    Article • Biologics Targets & Therapy, August 2008, Dove Medical Press

    Dr Camilo Porta, Prof Luciano Mutti

  98. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases

    Article • Mutation Research/Reviews in Mutation Research, July 2008, Elsevier

    Prof Luciano Mutti

  99. The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma

    Article • Oncology Reviews, April 2008, Springer Science + Business Media

    Prof Luciano Mutti

  100. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor

    Article • Mutation Research/Reviews in Mutation Research, March 2008, Elsevier

    Prof Luciano Mutti

  101. Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts

    Article • Clinical Cancer Research, January 2008, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  102. Is dronedarone effective for the prevention of recurrent atrial fibrillation?

    Article • Nature Clinical Practice Neurology, December 2007, Springer Science + Business Media

    Prof Luciano Mutti

  103. Bortezomib Inhibits Nuclear Factor- B Dependent Survival and Has Potent In vivo Activity in Mesothelioma

    Article • Clinical Cancer Research, October 2007, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  104. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

    Article • Oncogene, September 2007, Springer Science + Business Media

    Prof Luciano Mutti

  105. Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer

    Article • Clinical Cancer Research, September 2007, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  106. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

    Article • Thorax, August 2007, BMJ

    Prof Luciano Mutti

  107. Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma

    Article • International Journal of Cancer, January 2007, Wiley

    Prof Luciano Mutti

  108. Erionite and asbestos differently cause transformation of human mesothelial cells

    Article • International Journal of Cancer, January 2007, Wiley

    Prof Luciano Mutti

  109. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma

    Article • Cancer Chemotherapy and Pharmacology, April 2006, Springer Science + Business Media

    Prof Luciano Mutti

  110. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference

    Article • Annals of Oncology, April 2006, Oxford University Press (OUP)

    Prof Luciano Mutti

  111. A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma

    Article • Cancer Epidemiology Biomarkers & Prevention, July 2005, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  112. SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure

    Article • Cancer Research, June 2005, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  113. New Agents in the Management of Advanced Mesothelioma

    Article • Seminars in Oncology, June 2005, Elsevier

    Prof Luciano Mutti

  114. Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients

    Article • Lung Cancer, June 2005, Elsevier

    Prof Luciano Mutti

  115. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase

    Article • Molecular Cancer Therapeutics, May 2005, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  116. SV40 Enhances the Risk of Malignant Mesothelioma among People Exposed to Asbestos: A Molecular Epidemiologic Case-Control Study

    Article • Cancer Research, April 2005, American Association for Cancer Research (AACR)

    Prof Luciano Mutti

  117. Malignant Mesothelioma as both a challenge and an opportunity

    Article • Oncogene, November 2004, Springer Science + Business Media

    Prof Luciano Mutti

  118. SV40 and human brain tumors

    Article • International Journal of Cancer, June 2003, Wiley

    Dr. John A Lednicky, Prof Luciano Mutti

  119. Simian virus 40 and malignant mesothelioma (Review)

    Article • International Journal of Oncology, January 2003, Spandidos Publications

    Prof Luciano Mutti

  120. Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?

    Article • Lung Cancer, November 2002, Elsevier

    Prof Luciano Mutti

  121. Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines

    Article • Journal of Cellular Physiology, August 2002, Wiley

    Prof Luciano Mutti

  122. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications

    Article • British Journal of Cancer, March 2002, Springer Science + Business Media

    Prof Luciano Mutti

  123. The Presence of Simian-Virus 40 Sequences in Mesothelioma and Mesothelial Cells Is Associated with High Levels of Vascular Endothelial Growth Factor

    Article • American Journal of Respiratory Cell and Molecular Biology, February 2002, American Thoracic Society

    Prof Luciano Mutti

  124. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival

    Article • The Journal of Pathology, January 2002, Wiley

    Prof Luciano Mutti

  125. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma

    Article • Proceedings of the National Academy of Sciences, September 2001, Proceedings of the National Academy of Sciences

    Prof Luciano Mutti

  126. Basic fibroblast growth factor in mesothelioma pleural effusions: Correlation with patient survival and angiogenesis

    Article • International Journal of Oncology, May 2001, Spandidos Publications

    Prof Luciano Mutti

  127. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion

    Article • Lung Cancer, March 2001, Elsevier

    Prof Luciano Mutti

  128. Association of SV40 with human tumours

    Article • Seminars in Cancer Biology, February 2001, Elsevier

    Prof Luciano Mutti

  129. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

    Article • The Journal of Pathology, January 2001, Wiley

    Prof Luciano Mutti

  130. Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma

    Article • Human Pathology, November 2000, Elsevier

    Prof Luciano Mutti

  131. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma

    Article • Genes Chromosomes and Cancer, January 2000, Wiley

    Prof Luciano Mutti

  132. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma

    Article • Genes Chromosomes and Cancer, January 2000, Wiley

    Prof Luciano Mutti

  133. Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro

    Article • Journal of Cellular Physiology, January 2000, Wiley

    Prof Luciano Mutti

  134. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis

    Article • European Respiratory Journal, March 1999, European Respiratory Society (ERS)

    Prof Luciano Mutti

  135. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7–2 and can present recall antigens to autologous blood lymphocytes

    Article • International Journal of Cancer, December 1998, Wiley

    Prof Luciano Mutti

  136. New Target Therapies for Malignant Mesothelioma

    Article • Springer Science + Business Media

    Prof Luciano Mutti